Literature DB >> 16750163

Decreased cADPR and increased NAD+ in the Cd38-/- mouse.

Genevieve S Young1, Elena Choleris, Frances E Lund, James B Kirkland.   

Abstract

CD38 is a type II glycoprotein that catalyzes the formation of cyclic ADP-ribose (cADPR), an intracellular calcium signalling molecule, from nicotinamide adenine dinucleotide (NAD(+)). Using a modified version of the fluorimetric cycling assay for cADPR which reduces between-subject variability, we report significant decreases in brain and lung cADPR, which although similar to previously published values, showed much less individual variation. The reduced variation within each group suggests that the range of cADPR is narrower than previously thought, and that the regulatory mechanisms controlling these levels are more finely tuned. We also report significant increases in brain, lung, and kidney NAD(+) in the Cd38(-/-) mouse, and provide the first experimental demonstration of the proximate relationship between CD38 and NAD(+).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750163     DOI: 10.1016/j.bbrc.2006.05.100

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  46 in total

Review 1.  Signaling properties of CD38 in the mouse immune system: enzyme-dependent and -independent roles in immunity.

Authors:  Frances E Lund
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

2.  Metabolomic Endotype of Asthma.

Authors:  Suzy A A Comhair; Jonathan McDunn; Carole Bennett; Jade Fettig; Serpil C Erzurum; Satish C Kalhan
Journal:  J Immunol       Date:  2015-06-05       Impact factor: 5.422

Review 3.  NAD+ and sirtuins in aging and disease.

Authors:  Shin-ichiro Imai; Leonard Guarente
Journal:  Trends Cell Biol       Date:  2014-04-29       Impact factor: 20.808

Review 4.  Emerging roles of ADP-ribosyl-acceptor hydrolases (ARHs) in tumorigenesis and cell death pathways.

Authors:  Xiangning Bu; Jiro Kato; Joel Moss
Journal:  Biochem Pharmacol       Date:  2018-09-27       Impact factor: 5.858

Review 5.  NAD and the aging process: Role in life, death and everything in between.

Authors:  Claudia C S Chini; Mariana G Tarragó; Eduardo N Chini
Journal:  Mol Cell Endocrinol       Date:  2016-11-05       Impact factor: 4.102

6.  Evaluation of the NAD+ biosynthetic pathway in ALS patients and effect of modulating NAD+ levels in hSOD1-linked ALS mouse models.

Authors:  Benjamin A Harlan; Kelby M Killoy; Mariana Pehar; Liping Liu; Johan Auwerx; Marcelo R Vargas
Journal:  Exp Neurol       Date:  2020-01-31       Impact factor: 5.330

Review 7.  NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns.

Authors:  Hassina Massudi; Ross Grant; Gilles J Guillemin; Nady Braidy
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

Review 8.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 9.  CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions.

Authors:  Eduardo Nunes Chini
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Dual role of CD38 in microglial activation and activation-induced cell death.

Authors:  Lior Mayo; Jasmine Jacob-Hirsch; Ninette Amariglio; Gideon Rechavi; Marie-Jo Moutin; Frances E Lund; Reuven Stein
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.